LexaGene (LXXGF) – Molecular diagnostics company with great upside due to high margin “razor blade” business modelThis is a molecular diagnostics company that has been mentioned here a few times, as it has been teased in a few newsletters. I have been invested in this company since 2019. I increased my position greatly after I saw a free youtube interview where Dr. KSS was interviewing the CEO. (I did not know […]
Articles
Yes, in the midst of a severe global surge in new cases and deaths, there are several genuinely good news items that we can pin our hopes on. Surely, you are aware of some of these, but I will attempt to put them in context. As of yesterday, from the start of pandemic to […]
As I write this, both the US and the world are seeing an upsurge in COVID-19. There has been a 46% spike in hospitalized patients, and in the past seven days more than a half-million more Americans have contracted the coronavirus. According to the Johns Hopkins dashboard that tracks COVID-19 cases all over the world, […]
So now, more than six months after this pandemic was officially declared, some experts are telling us that the COVID-19 testing that we have been doing is all wrong, and that a totally different form of testing could be an effective way to end the pandemic. What they are saying is that the scientific […]
This will surely not be the last time Doc Gumshoe turns his attention to the pandemic that is now imposing misery on many parts of the world. I need to acknowledge that when what was then generally called the Wuhan virus first came to my attention, I expressed the view that, despite the dire […]
Today we’re headed into the wild and woolly world of biotech once again, sniffing out the secret stock from a teaser pitch for Biotech Millionaire, edited by Chris Wood and Jake Weber over at Mauldin Economics ($1,795/yr, includes their Healthy Returns letter… and unlike most higher-cost letters these days, they actually offer a 30-day refund […]
This article was originally published on May 28, 2020, when we first saw these ads — they have recently been re-circulating as the June 30 date approaches and vaccine interest rises again. What follows has not been updated since May 28, though I did add an updated note at the bottom. We haven’t covered a […]
It’s not as though the pandemic has cleared the decks of all other health-related issues. I’m sorry to report that people still have heart attacks, strokes, and cancer as well as all the plethora of other ailments, diseases, and conditions that affect our species. For example, I was thinking of putting in a […]
We saw a big recovery over the past week or so from those cyclical stocks that were hurt by coronavirus, as the excitement about reopening and vaccine development sends people out of direct beneficiaries of the outbreak like Teladoc (TDOC) and the stuck-at-home names and into the stocks that were most hurt by the shutdown. […]
I decided to add the year to my title in the event that this thing goes on for another full year, and I have to do an update in May 2021. I pray fervently that such an eventuality will not come to pass, but it’s certainly possible. Having said that, your obedient servant […]
It’s hard to stay away from the coronavirus pandemic, even though Doc Gumshoe basically has no information that’s any different from what’s flooding into your inboxes or TV screens or, for those of us who are still members of the ancient fellowship of newspaper readers, the pages of our daily newspapers. But a few […]
Today I’m getting a lot of questions about the “Coronavirus Recovery Package” being pitched by Alexander Green — he’s selling Oxford Club subscriptions ($99) by promising a special report called “The Three Biggest Winners of the Coronavirus Recovery.” Green’s big-picture intro is pretty reasonable and rational, and similar to lots of other folks these days […]
I’ve gotten a few questions about the latest Technology Profits Confidential (currently $79/yr) tease from Ray Blanco, so although it’s a few weeks old now, and started circulating right in the heat of the first coronavirus downturn in mid-March, I thought I’d take a look today. It is still a current ad, I got it […]
It’s been a wild week. The mood was still pretty upbeat on Monday and Tuesday, a little anxiety but a lot of complacency (including mine)… I was in Toronto early this week, with plenty of hand washing and hand sanitizer but no real signs of panic or changes in lifestyle for most folks — the […]
This is the latest teaser pitch that a lot of folks have been asking about — and rightly so, I expect, because it’s designed to be extremely topical and get you revved up immediately. Here’s the intro to the ad that I’ve seen in some Angel Publishing newsletters: “We’re now in crisis mode over coronavirus […]
It’s been an unusually active month in the Real Money Portfolio — a couple big sells, several brand new positions, and quite a bit more churn than I usually have. Those transactions have mostly been fairly small, the largest position that I opened or closed was the sale of my sub-2% Facebook position, but that’s […]
It’s been a roller coaster ride so far this week. I’m a beginner in investing and waiting for the market selloff to reach the bottom. Given the situation that coronavirus just started spreading in US, anyone who can read the situation comment on what could be possible bottom or did we already reach it with […]
This is an update of a teaser solution from an older Friday File for everyone to read… I figure the Irregulars won’t be too upset, since the stock in question is up dramatically since this piece was published, but it’s still an interesting story — and a stock I own and would like to buy […]
Having just devoted an entire Doc Gumshoe piece to the notorious coronavirus (COVID 19), I’m going to make those coronavirus updates brief – it looks to me as though the news media is devoting a major part of its capacity to covering most aspects of this pandemic – and, yes, it now certainly looks like […]
It’s been a wild ride for the past couple weeks of coronavirus panic, and this week has been especially crazy (and still isn’t quite over)… though it’s encouraging that my Real Money Portfolio has been a little bit stronger than the market so far this year — partly because of brilliant stock selection, I’d like […]
Don’t look to Doc Gumshoe to keep you up to the minute on the spread of the Wuhan coronavirus. The figures I’m quoting below are as of mid-day today, February 18th. These will have changed by the time you see this piece, and they may be unreliable in the first place. But, […]
Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw. My impressions and conclusions are in some cases only loosely based on […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
BTW, Vanguards International Fund VWIGX is up 8.05 % already Year-To-Date (YTD 1/20/2021) this year and was up 59% for ...
A mistake is noted in the article. With a 95% effective virus, you would NOT have a one in twenty chance of getting the...
'If I were to be vaccinated with one of those vaccines that are 95% efficacious, I would still have a one out of twenty ...
Pandemic? Death rate about 2%. SARS in 2002 had a rate of death closer to 10%. The world wasn't shut down for that. ...
FDA grants first emergency use authorization for at-home rapid coronavirus test November 18, 2020 / 8:02 AM / AP U...
Check out the Moderna Aug 11, 2020 8-K filing: "The U.S. Supply Agreement provides for the manufacturing and delivery ...
Cytodyn will be reporting on P2 M2M results within 2 weeks, and DSMC is taking a look at their S/C P2b/P3 trial this wee...
Yes, there is the small possibility that a vaccine could make your reaction to the pathogen worse. That's one of the th...
I'm surprised you didn't bring up leronlimab. Mark this note....it will be the leading therapy for COVID-19 in short or...
Regarding C19 treatments, one you should keep your eye on is Leronlimab from Cytodyn, a small cap pharma. A BLA for HIV...
Agreed... My money is on CYDY for HIV and cancer, but C19 trials are eye opening.... This coming week will tell the tail...
In 1979 I began college for a pharmacy degree. My father in law was an emeritus professor at University of Michigan sch...
CEO of Co-Diagnostics $CODX was on Varney (FBN) on 3/5 mentioning the fact that recent relaxation of FDA restrictions no...
Headline from 3/1: Vaxart, Inc. (NasdaqGS: VXRT), a clinical-stage biotechnology company developing oral recombinant vac...
TOMZ recent headline: https://finance.yahoo.com/news/steramist-declared-official-decontamination-technology-143010170.ht...
Just some ideas: "CODX", maker of diagnostic kits for Covid-19 could go vertical once approved by FDA/CDC. The stock ha...
Great and informative article from a medical prospective. What stocks do u all think will rally, even if temporarily, du...